Sotigalimab
- Generic Name
- Sotigalimab
- Drug Type
- Biotech
- CAS Number
- 2305607-45-6
- Unique Ingredient Identifier
- JEA93WJ5DG
- Background
Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVB Colorectal Cancer AJCC v7Metastatic Colorectal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage IVA Colorectal Cancer AJCC v7Stage IV Colorectal Cancer AJCC v7
- Interventions
- Biological: Synthetic Tumor-Associated Peptide Vaccine TherapyProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT02600949
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Phase 1
Completed
- Conditions
- CancerUrothelial CarcinomaHead and Neck CancerNSCLCMSI-HMelanoma
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02482168
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath